The new studies, published in the journal Molecular Cell, come from the Institute of Biochemistry at ETH Zurich, led by professors Ulrike Kutay, Karsten Weis and Madhav Jagannathan, together with colleagues from the University of Fribourg, the Paul Scherrer Institute, the European Molecular Biology Laboratory and RWTH Aachen University. Their work demonstrates for the first time that two molecular tools are required for the two membranes of the nuclear envelope to fuse correctly: an enzyme called Torsin-1A and a complex built from multiple copies of a protein known as CLCC1 in human cells. In fungi, the same job is carried out by the related proteins Brl1 and Brr6, a detail that underscores how deeply conserved this fusion machinery is across the tree of life, from yeast to flies to mammals.

Until now, scientists knew that a defect in Torsin-1A brings nuclear pore assembly to a halt, with fatal consequences for the cell, but the mechanics of the partnership remained obscure. The ETH-led teams have now shown how the cooperation works at a molecular level. Torsin-1A binds to CLCC1 and helps several of these building blocks join together into a larger assembly. Once the complex is formed, Torsin-1A escorts it to the site of pore assembly on the nuclear envelope, positioning it exactly where the two membranes must merge. In other words, the enzyme acts both as a chaperone that assembles the fusion machinery and as a guide that delivers it to its workplace.

The fusion mechanism itself caught the researchers off guard. Using computer simulations, the teams hypothesised that CLCC1 proteins, or their fungal relatives Brl1 and Brr6, forge a temporary channel inside the nuclear envelope. This channel allows lipid molecules to flow across the bilayers, a movement that is normally restricted. The resulting lipid exchange destabilises the local membrane structure and forces the inner and outer nuclear membranes to fuse with one another. Daria Maslennikova, the first author of one of the studies, who completed her doctorate in Kutay’s group, said the teams had not expected such a mechanism. The idea that a protein complex could catalyse membrane merger by opening a lipid conduit, rather than by directly pulling the membranes together, adds a striking new entry to the catalogue of ways cells remodel their internal boundaries.

The stakes of this microscopic operation become clear when it fails. In higher organisms such as mammals, flies and fungi, the genome is enclosed in a nucleus bounded by a nuclear envelope of two stacked membranes. Nuclear pores are the only conduits through the envelope, and each one must be assembled by fusing the inner and outer membranes at a single point. If fusion stalls, pore assembly stalls with it, and the vital traffic of proteins and RNA between nucleus and cytoplasm is compromised. Cells that cannot build their pores cannot survive, which is why the machinery described in the new papers is so critical, and why mutations that impair it produce disease.

That disease is primary dystonia, specifically DYT1 dystonia, a rare and currently incurable neurological movement disorder that affects roughly six in every 100,000 people worldwide. The condition usually begins in childhood and manifests as painful muscle spasms and abnormal postures that can be severely disabling. Treatment options today are limited to alleviating symptoms, chiefly through physiotherapy or injections of botulinum toxin, and no therapy addresses the underlying cause. The new findings give that cause a molecular identity: in people with primary dystonia, a mutation in the Torsin1A gene prevents the Torsin1A molecule from functioning correctly, leaving the CLCC1 complex without sufficient support to carry out its membrane-fusion duties during nuclear pore assembly.

Crucially, the research also points toward a possible intervention. In experiments with fruit flies, the researchers showed that artificially increasing CLCC1 levels can correct defects that arise, for example, during germline cell development, even when Torsin-1A function is impaired. This suggests that the CLCC1 complex is the limiting factor in the fusion reaction, and that boosting its availability can compensate for a weakened partner enzyme. The result transforms a fundamental cell-biological discovery into a concrete therapeutic hypothesis: if the balance between Torsin1A and CLCC1 can be shifted in patients, the cellular defects that drive dystonia might be partially or fully corrected.

One lingering mystery is why the same Torsin1A mutation produces symptoms in only about a third of the people who carry it. The researchers speculate that person-specific differences in CLCC1 protein levels may contribute to this variable penetrance, meaning that individuals with naturally higher amounts of the fusion protein might be better buffered against the effects of the faulty enzyme. If that hypothesis holds up, measuring or modulating CLCC1 levels could become not only a treatment strategy but also a way to predict who is at risk. Ulrike Kutay noted that the finding helps the team envision a possible therapy, with one potential strategy being to boost CLCC1 production or to prevent the protein from being broken down inside cells. This approach has already shown success in human cell cultures and in fruit flies, although whether it can be translated to patients must first be evaluated in further clinical studies and drug screens.

Beyond the immediate therapeutic horizon, the work opens several new lines of inquiry. The teams plan to investigate additional relatives of Torsin1A; human cells contain other torsins whose precise functions remain unknown, and the tools and concepts developed in this study should now make those functions accessible to experiment. In collaboration with plant scientists, Kutay, Weis, Jagannathan and their colleagues also aim to determine whether similar molecules and fusion mechanisms operate in plants, which would indicate that the pathway is a universal feature of eukaryotic life. For the researchers, the journey from a basic question about how cells punch holes in their own nucleus to a candidate therapy for a devastating childhood disease is a powerful illustration of why curiosity-driven research matters. Fundamental discoveries about the smallest building blocks of life, they argue, remain the most reliable starting point for the medicines of tomorrow.

Subject of Research: Membrane fusion mechanism of nuclear pore complex assembly and its link to DYT1 dystonia

Article Title: How cells make their command center accessible

Article References: How cells make their command center accessible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear pore complex, nuclear envelope, membrane fusion, Torsin-1A, CLCC1, DYT1 dystonia, ETH Zurich, Molecular Cell, cell biology, neurological disorder, gene mutation, basic research

Lung cancer remains the most commonly diagnosed and deadliest malignant tumor worldwide, and while radical surgical resection is the treatment of choice for early-stage disease, postoperative recurrence continues to undermine long-term outcomes for a substantial fraction of patients. The clinical dilemma is familiar to every thoracic oncologist: two patients with seemingly identical tumor stage and histology can follow radically different trajectories after surgery, one remaining disease-free for a decade, the other relapsing within a year. Traditional staging, based on tumor size, nodal involvement and metastatic status, captures only part of this biological heterogeneity. The Shanghai team set out to determine whether the mutational landscape of resected tumors could close that gap, systematically delineating the gene mutation profile of a large real-world Chinese cohort and assessing the predictive value of critical mutations for postoperative disease-free survival (DFS).

The methodology was comprehensive. All 1,674 enrolled patients, treated between long follow-up windows and retrospectively identified from clinical records, had undergone NGS-based molecular profiling of their resected tumor specimens. The investigators collected detailed clinicopathological data, treatment information and survival outcomes, then constructed mutation profiles for the overall population and for clinically relevant subgroups. Statistical machinery included Kaplan-Meier survival curves to visualize differences in disease-free survival, univariate and multivariate Cox proportional-hazards regression to isolate the independent contribution of each genetic and clinical variable, and co-mutation analysis to test whether pairs of altered genes interact to shape prognosis more than either alteration alone.

The mutational census that emerged was broad: 144 relevant mutated genes were detected across the cohort, and the team mapped their frequencies across the population. Two alterations dominated the landscape. EGFR, the epidermal growth factor receptor gene long known to be unusually frequent in East Asian lung cancer populations, was mutated in 61.2 percent of patients, while TP53, the canonical guardian-of-the-genome tumor suppressor, was altered in 31.9 percent. The high EGFR prevalence itself underscores why population-specific genomic studies matter; mutation frequencies observed in predominantly Western cohorts do not simply translate to Chinese patients, and treatment guidelines built on foreign data risk misaligning with the biology of the patients they are meant to serve.

The prognostic signal, however, came less from EGFR than from a set of other genes. Univariate analysis revealed that patients harboring mutations in TP53, KRAS, MET, ROS1 or CDKN2A experienced significantly shorter disease-free survival than patients without those alterations. In contrast, and perhaps counterintuitively, ERBB2 mutations were associated with longer DFS, a finding that held up when the investigators pushed the data through multivariate modeling. That final model, which adjusted for confounders simultaneously, confirmed TP53 mutation, ERBB2 mutation, tumor and nodal stage (T/N classification) and pleural invasion as independent prognostic factors for postoperative disease-free survival. In other words, even after accounting for how advanced a tumor appeared anatomically, the mutational status of these genes carried genuine, standalone predictive information about whether a patient’s cancer would return.

The most consequential result concerned gene pairs. When the team performed co-mutation analysis, patients whose tumors carried both TP53 and MET mutations had the poorest prognosis of any molecular subgroup, with disease-free survival significantly worse than that of patients carrying either single mutation and dramatically worse than those wild-type for both genes. This synergistic worsening of outcome is biologically plausible: TP53 loss disables apoptotic safeguards and genomic integrity checks, while MET activation drives invasive growth and metastatic signaling pathways, and the combination may equip residual micrometastatic disease with a particularly aggressive phenotype. Critically, the TP53-MET co-mutation signal remained consistent when the analysis was repeated in the subgroup of patients whose disease did progress, reinforcing the robustness of the association rather than reflecting a statistical artifact of the full cohort.

For clinical practice, the implications are tangible. Postoperative risk stratification for lung cancer currently leans heavily on pathological stage, with adjuvant therapy decisions guided largely by nodal status and tumor size. This study provides evidence that NGS profiling of resected specimens can refine that stratification: a patient with a TP53-mutant tumor, or worse, a TP53 and MET co-mutant tumor, could be flagged for intensified surveillance imaging, consideration of adjuvant targeted therapy or chemotherapy trials, and earlier detection of recurrence through molecular monitoring. Conversely, an ERBB2-mutant patient with otherwise favorable anatomy may face a lower recurrence risk than staging alone would suggest, information that could spare unnecessary treatment toxicity. The authors explicitly frame the results as a reliable molecular basis for postoperative risk stratification and individualized adjuvant therapy in lung cancer.

The study’s scale and design give its conclusions unusual weight. Retrospective cohort studies of this kind are vulnerable to selection bias and to the vagaries of heterogeneous treatment patterns, but a sample of 1,674 consecutively sequenced patients with long-term follow-up is rare in the literature on resected lung cancer, and the concordance between univariate, multivariate and co-mutation analyses, together with validation in the progression subgroup, argues that the signals are genuine properties of the disease rather than artifacts. The work was approved by the Ethics Committee and Institutional Review Board of Shanghai Chest Hospital under reference number LS1808, conducted in line with the Declaration of Helsinki, and supported by the National Natural Science Foundation of China and the Chinese Society of Clinical Oncology. Corresponding authors Zhi-qiang Gao, Jun Lu and Bao-hui Han led the effort, with Feng Pan and Liang Zheng contributing equally as first authors.

What remains to be established is prospective validation. Retrospective association, however robust, must ultimately be tested in trials that assign adjuvant treatment based on mutational profile and measure whether outcomes improve; ongoing studies of adjuvant targeted therapy in EGFR-mutant disease suggest this paradigm is already moving into the clinic. The Shanghai data add momentum by identifying which patients, within the large EGFR-mutated population, are most and least likely to benefit from closer surveillance. As NGS testing becomes routine and cheaper for resected lung cancer specimens, studies like this one chart the path from genomic description to genomic prognosis, where every surgical specimen yields not just a diagnosis but a personalized forecast, and where the risk of recurrence, lung cancer’s most feared late event, can be anticipated and countered before the first recurrent cell ever shows up on a scan.

Subject of Research: Postoperative gene mutations as prognostic predictors of disease-free survival in Chinese patients with resected lung cancer

Article Title: Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study

Article References: Pan, F., Zheng, L., Zhang, L.-L., Wang, X., Lu, A.-T., Zhou, C., Gao, Z.-Q., Lu, J., & Han, B.-H. (2026). Relationship between postoperative gene mutation and prognosis in chinese patients with lung cancer: a long-term follow-up retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16960-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16960-w

Keywords: lung cancer, gene mutation, TP53, EGFR, MET, disease-free survival, next-generation sequencing, postoperative recurrence, prognostic factors, co-mutation, retrospective cohort study, adjuvant therapy